Skip to main content

Table 9 Net budget impact due to adoption of epoetin SEBs for years 1 to 5, and cumulative impact over 5 years

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Year Total drug cost in without SEB scenario ($) Total drug cost in SEB scenario ($) Net budget impact ($)
Year 1 262,665,144 228,045,878 −34,619,266
Year 2 293,803,997 253,494,088 −40,309,908
Year 3 317,499,168 272,223,786 −45,275,381
Year 4 330,514,535 281,003,457 −49,511,077
Year 5 329,951,320 278,742,875 −51,208,445
Cumulative total 1,534,434,163 1,313,510,085 −220,924,078
  1. SEB = subsequent entry biologic.